Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024281 | 0.94 | ACE2 (0.36) | TSHRACE2LMNAADH1BADH1C | |
| SCHEMBL3024990 | 0.92 | TSHR (0.39) | TSHRACE2LMNAADH1BADH1C | |
| SCHEMBL3034088 | 0.87 | TSHR (0.37) | TSHR | |
| SCHEMBL3038369 | 0.85 | TSHR (0.31) | TSHRSMN1; SMN2 | |
| SCHEMBL3043256 | 0.83 | TSHR (0.39) | TSHRACE2LMNAADH1BADH1C | |
| SCHEMBL8811039 | 0.83 | LMNA (0.52) | LMNA | |
| SCHEMBL3035339 | 0.83 | LMNA (0.52) | LMNA | |
| SCHEMBL3024812 | 0.82 | ACE2 (0.44) | TSHRACE2LMNAADH1BADH1C | |
| SCHEMBL21908693 | 0.81 | — | — | |
| SCHEMBL3034938 | 0.80 | ACE2 (0.47) | TSHRACE2ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | MATSUDA, AKIRA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2045256-A1 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0519370-B1 | Heterocyclic derivatives | MERCK PATENT GMBH (DE) | 1997-11-05 | — | — | EP | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0413785-B1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS | MERCK PATENT GMBH (DE) | 1995-12-20 | — | — | EP | disclosed |
| EP-0394906-B1 | Liquid crystalline composition | MERCK PATENT GMBH (DE) | 1995-12-20 | — | — | EP | disclosed |
| EP-0423520-B1 | Liquid crystalline composition for the use in a twisted nematic cell | MERCK PATENT GMBH (DE) | 1995-08-02 | — | — | EP | disclosed |
| EP-0445248-B1 | PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1995-03-08 | — | — | EP | disclosed |
| EP-0445248-A1 | PYRIDINE DERIVATIVES. | MERCK PATENT GMBH (DE) | 1991-09-11 | — | — | EP | disclosed |
| EP-0429574-A1 | CHLOROBENZENE DERIVATIVES | MERCK PATENT GmbH (DE) | 1991-06-05 | — | — | EP | disclosed |
| EP-0425624-A1 | FLUORINATED CYCLOHEXYL DERIVATIVES | MERCK PATENT GmbH (DE) | 1991-05-08 | — | — | EP | disclosed |
| WO-1991004248-A1 | PYRIDINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-04-04 | — | — | WO | disclosed |
| EP-0413785-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS. | MERCK PATENT GMBH (DE) | 1991-02-27 | — | — | EP | disclosed |
| WO-1990015115-A1 | FLUORINATED BIPHENYL DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-12-13 | — | — | WO | disclosed |
| WO-1990014405-A1 | CHLOROBENZENE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-11-29 | — | — | WO | disclosed |
| WO-1990014406-A1 | FLUORINATED CYCLOHEXYL DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-11-29 | — | — | WO | disclosed |
| EP-0394906-A2 | Liquid crystalline composition | MERCK PATENT GmbH (DE) | 1990-10-31 | — | — | EP | disclosed |
| WO-1990009420-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | NUDT1, DPYD, SLC29A1 | TSHR 2498/4885ACE2 1401/4885LMNA 1804/4885 |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | NUDT1, DPYD, SLC29A1 | TSHR 2498/4885ACE2 1401/4885LMNA 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.